NeuroCentrix - Early Alzheimer's Treatment & Research

17/05/2022

Prof David Barton speaks about dementia, depression, and the brain with Tiffanee Cook of the Roll With The Punches podcast.

Listen to this conversation on Apple podcast app:

https://podcasts.apple.com/au/podcast/ep142-depression-dementia-brain-professor-david-barton/id1520188386?i=1000522231300?utm_source=neurocentrix

Or Spotify:

https://open.spotify.com/episode/6oNzbR5ePDo7jDifMU6FjQ?utm_source=neurocentrix

Or any podcast player of your choice.

11/08/2021

Alzheimer’s Disease has been blamed on the build-up of two particularly nasty proteins in the brain: beta-amyloid and tau.

Amyloid accumulates in plaques outside neurons, while tau twists into tangles inside. These are the characteristic plaques and tangles seen in the post-mortem Alzheimer’s brain. Patients may still function reasonably well with large amyloid deposits, but life’s curtain is certainly falling once the tendrils of tau take hold. By then the patient is not just losing his keys, but forgetting what they’re called, or even how to use them.

What makes tau so toxic, and what’s it doing there in the first place?

Answering these questions may unlock the riddle of one of humanity’s most devastating afflictions.

Full article:

August 11, 2021August 11, 2021 by Luke Ainsworth Alzheimer's, beta-amyloid and tau: research continues The culprits: beta-amyloid and tau Alzheimer’s Disease has been blamed on the build-up of two particularly nasty proteins in the brain: beta-amyloid and tau.Amyloid accumulates in plaques outside...

15/06/2021

Three FDA advisers resigned over new Alzheimer's drug approval.

Here's why:

https://neurocentrix.com.au/controversy-approval-aduhelm-alzheimers/

NeuroCentrix is a private neuroscience facility dedicated to evidence-based assessment, treatment and research of memory and mood disorders.

01/06/2021

Laughter is a human universal, found in all cultures, everywhere, in all times. Yet there is no clear reason why we get a burst of joy when something is funny, and even after centuries of trying, we can’t precisely define what “funny” is.

We can understand jokes but usually can’t explain what it is about them that makes us laugh. Whenever we can, they aren’t as funny.

All this is very strange. How can we understand and not understand something at the same time?

https://neurocentrix.com.au/why-do-we-laugh/

NeuroCentrix is a private neuroscience facility dedicated to evidence-based assessment, treatment and research of memory and mood disorders.

03/05/2021

Is there a mainstream role for the drugs of the counterculture?

Psilocybin (the active element of magic mushrooms) and L*D (also known as acid) were research darlings in the 1950s with hopes that they could cure depression, drug addiction and even the fear of mortality. But by 1970, both were banned in the United States as drugs with high potential for abuse and no medical role.

https://neurocentrix.com.au/psychedelics/

26/04/2021

Alzheimer’s disease features the build-up of two distinct proteins in the brain: beta-amyloid, which accumulates in clumps, and tau, in tangles. But how exactly they relate to each other and the death of neurons has remained a mystery – perhaps until now.

Alzheimer’s disease features the build-up of two distinct proteins in the brain: beta-amyloid, which accumulates in clumps, and tau, in tangles. But how exactly they relate to each other and the death of neurons has remained a mystery – perhaps until now.Are we closer to finding the Alzheimer’...

20/04/2021

Artificial intelligence in Alzheimer's research - read about the latest developments.

New drugs to treat Alzheimer’s are desperately needed – but new drugs are extremely hard to find. The team here at Neurocentrix are trialling several promising drugs and are all-too familiar with the long and painstaking process needed to bring a medication to the market.Researchers today use ma...

15/04/2021

Can we grow new neurons? Find out more about how to take advantage of new science in the field of Alzheimer's Disease research.

At medical school we learnt very few certainties. Everything was a possibility, a probability, a risk, a trend, a likelihood. There were many rules of thumb, but very few rules. Yet amongst all the qualified circumspection, there was one iron-clad law:The human brain grows no new neurons.All the neu...

06/04/2020

A Clinical Trial in Early Alzheimer’s Disease - The ANAVEX2-73 Study

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects memory and other normal brain functions.

ANAVEX2-73 is a new small molecule that has been shown in previous research studies to improve mental activities that are involved in learning, remembering and using general daily knowledge. These results may indicate that ANAVEX2-73 has protective properties on the brain neurons that are usually damaged in Alzheimer’s disease.

This study medication is an oral formulation. To compare how well this drug works, patients will randomly be assigned to 3 different groups: 50 mg ANAVEX2-73; 30mg ANAVEX2-73; and placebo (1:1:1). Therefore, all participants have a 2 in 3 chance of receiving the investigational product ANAVEX2-73.

This study will require participation for approximately 48 weeks, including 6 on- site visits during that period.

MAIN INCLUSION CRITERIA*:

- Age- 60-85 years;
- Availability of a study partner, who spends at least 10 hrs per week with the participant;
- If receiving medication for symptomatic AD, have a stable dosing regimen for 3 months prior screening.

*Please note that there are additional criteria that must be met in order to qualify to participate in this study.

https://neurocentrix.com.au/anavex-trial

24/01/2019

A simple blood test that could detect signs of brain damage and predict early Alzheimer's, Click on the following link to find out more: https://www.smh.com.au/national/blood-test-could-predict-early-alzheimer-s-scientists-say-20190123-p50t4w.html

01/11/2018

What is magnetic brain stimulation and how does it treat Alzheimer's? Find out in this link:

Learn how the non-invasive procedure of repetitive transcranial magnetic stimulation may improve the cognitive functioning of people with Alzheimer's.